Literature DB >> 26686260

Patients' reluctance to undergo deep brain stimulation for Parkinson's disease.

Mi-Ryoung Kim1, Ji Young Yun2, Beomseok Jeon3, Yong Hoon Lim1, Kyung Ran Kim1, Hui-Jun Yang4, Sun Ha Paek5.   

Abstract

BACKGROUND: Many patients with advanced Parkinson's disease (PD) are reluctant to undergo the subthalamic nucleus deep brain stimulation (STN-DBS) when surgery is warranted. Reasons for this reluctance have not been examined. We undertook to establish the rate and causes of this reluctance for STN-DBS in patients with advanced PD.
METHODS: A reluctant group was defined as patients who were hesitant to undergo DBS. Clinical information included age, onset age, disease duration, the Unified Parkinson Disease Rating Scale, Hoehn and Yahr stage and levodopa equivalent dose when they were evaluated with a view to consider surgery.
RESULTS: We enrolled 186 patients who underwent STN-DBS. 84 patients (45%) belonged to the reluctant group. Between the reluctant and the non-reluctant, there were no differences in preoperative characteristics. Main reasons for hesitation were fear of complications (74%) and economic burden (50%). The main reasons that they finally underwent the DBS were confidence in the doctor's decision (80%) and encouragement from their family (36%).
CONCLUSIONS: Building trust between patients and physicians is an important factor in guiding patients to undergo this treatment. To reduce the reluctance to undergo DBS at the appropriate time, we need to find effective ways of reducing their psychological and economic burden.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Deep brain stimulation; Motor control; Parkinson's disease

Mesh:

Year:  2015        PMID: 26686260     DOI: 10.1016/j.parkreldis.2015.11.010

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

Review 1.  Neuromodulation interventions for addictive disorders: challenges, promise, and roadmap for future research.

Authors:  Primavera A Spagnolo; David Goldman
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

2.  Complex therapies for advanced Parkinson's disease: what is the role of doctor-patient communication?

Authors:  Elisa Montanaro; Carlo Alberto Artusi; Maurizio Zibetti; Leonardo Lopiano
Journal:  Neurol Sci       Date:  2019-06-28       Impact factor: 3.307

3.  Deep Brain Stimulation in Early-Stage Parkinson's Disease: Patient Experience after 11 Years.

Authors:  Kaitlyn Stoehr; Kian Pazira; Kemberlee Bonnet; David Schlundt; David Charles; Mallory Hacker
Journal:  Brain Sci       Date:  2022-06-11

4.  Is deep brain stimulation therapy underutilized for movement disorders?

Authors:  Aparna Wagle Shukla; Wissam Deeb; Bhavana Patel; Adolfo Ramirez-Zamora
Journal:  Expert Rev Neurother       Date:  2018-11-15       Impact factor: 4.618

5.  Economic Burden Analysis of Parkinson's Disease Patients in China.

Authors:  Jun-Xiu Yang; Lei Chen
Journal:  Parkinsons Dis       Date:  2017-06-14

6.  Thalamotomy for essential tremor: FDA approval brings brain treatment with FUS to the clinic.

Authors:  Paul S Fishman
Journal:  J Ther Ultrasound       Date:  2017-07-13

Review 7.  MRI-Guided Focused Ultrasound in Parkinson's Disease: A Review.

Authors:  Ilana Schlesinger; Alon Sinai; Menashe Zaaroor
Journal:  Parkinsons Dis       Date:  2017-03-30

8.  Access and Use of Device-Aided Therapies for Parkinson's Disease in Denmark.

Authors:  Tove Henriksen; Kim Peder Dalhoff; Henriette Engel Hansen; Andreas W Brenneche; Ulla Sofie Lønberg; Erik Hvid Danielsen
Journal:  Mov Disord Clin Pract       Date:  2020-07-02

9.  Involving Patients in Weighting Benefits and Harms of Treatment in Parkinson's Disease.

Authors:  Marieke G M Weernink; Janine A van Til; Jeroen P P van Vugt; Kris L L Movig; Catharina G M Groothuis-Oudshoorn; Maarten J IJzerman
Journal:  PLoS One       Date:  2016-08-30       Impact factor: 3.240

10.  Stimulating Solutions for Intractable Epilepsy.

Authors:  Timothy Denison; Mohamad Koubeissi; Esther Krook-Magnuson; David Mogul; Gregory Worrell; Catherine Schevon
Journal:  Epilepsy Curr       Date:  2021-04-30       Impact factor: 7.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.